Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model

Journal of Controlled Release

Volumn 162, Issue 1, 2012, Pages 9-18

  Kim, Pyung Hwan ^a   Lee, Minhyung ^b   Kim, Sung Wan ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Hanyang University   (South Korea)

Author keywords

Diabetes; Exendin 4 polyplex; Gene delivery; TSTA system

Indexed keywords

ALTERNATIVE METHODS; ANIMAL MODEL; BIOREDUCIBLE POLYMER; BLOOD GLUCOSE LEVEL; CLINICAL APPLICATION; DIABETIC MICE; EXPRESSION SYSTEM; FOOD INTAKE; GASTRIC EMPTYING; GENE CARRIER; GENE DELIVERY; GLUCOSE CONCENTRATION; IN-VITRO; IN-VIVO; INSULIN SECRETION; INSULINOMA CELLS; INSULINOTROPIC EFFECTS; INTRAVENOUS ADMINISTRATION; POLYPLEXES; SIGNAL PEPTIDE; THERAPEUTIC AGENTS; TSTA SYSTEM; TYPE-2 DIABETES;

AMPLIFICATION; ARGININE; BIOCHEMISTRY; CELL PROLIFERATION; DEGRADATION; GENE THERAPY; GENE TRANSFER; GLUCOSE; INSULIN; MAMMALS; MEDICAL PROBLEMS; PHYSIOLOGY; TISSUE; TRANSCRIPTION;

POLYMERS;

ARGININE; CYCTAMINEBISACRYLAMIDE; DIAMINOHEXANE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; POLY(DISULFIDE AMINE); POLYMER; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; GENE AMPLIFICATION; GENETIC TRANSCRIPTION; IN VITRO STUDY; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ARGININE; BLOOD GLUCOSE; CELL LINE; DIABETES MELLITUS, TYPE 2; DNA; DRUG CARRIERS; GENE EXPRESSION; GENETIC THERAPY; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; PEPTIDES; PLASMIDS; POLYMERS; TRANSCRIPTION, GENETIC; VENOMS;

EID: 84864648267     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.06.010     Document Type: Article

References (29)

1. S.W. Kim Polymeric gene delivery for diabetic treatment Diabetes Metab. J. 35 2011 317 326
2. Y. Li, T. Hansotia, B. Yusta, F. Ris, P.A. Halban, and D.J. Drucker Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis J. Biol. Chem. 278 2003 471 478
3. P.L. Brubaker Minireview: update on incretin biology: focus on glucagon-like peptide-1 Endocrinology 151 2010 1984 1989
4. B. Ahren The future of incretin-based therapy: novel avenues-novel targets Diabetes Obes. Metab. 13 Suppl. 1 2011 158 166
5. E.J. Verspohl Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors Pharmacol. Ther. 124 2009 113 138
6. L.L. Nielsen, A.A. Young, and D.G. Parkes Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes Regul. Pept. 117 2004 77 88
7. G. Bertilsson, C. Patrone, O. Zachrisson, A. Andersson, K. Dannaeus, J. Heidrich, J. Kortesmaa, A. Mercer, E. Nielsen, H. Ronnholm, and L. Wikstrom Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease J. Neurosci. Res. 86 2008 326 338
8. B. Martin, E. Golden, O.D. Carlson, P. Pistell, J. Zhou, W. Kim, B.P. Frank, S. Thomas, W.A. Chadwick, N.H. Greig, G.P. Bates, K. Sathasivam, M. Bernier, S. Maudsley, M.P. Mattson, and J.M. Egan Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease Diabetes 58 2009 318 328
9. Z. Wu, I. Todorov, L. Li, J.R. Bading, Z. Li, I. Nair, K. Ishiyama, D. Colcher, P.E. Conti, S.E. Fraser, J.E. Shively, and F. Kandeel In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor Bioconjug. Chem. 22 2011 1587 1594
10. L.R. Ranganath Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 J. Clin. Pathol. 61 2008 401 409
11. N. Mikhail Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes Expert Opin. Investig. Drugs 17 2008 845 853
12. C.A. Schnabel, M. Wintle, and O. Kolterman Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes Vasc. Health Risk Manag. 2 2006 69 77
13. M. Szayna, M.E. Doyle, J.A. Betkey, H.W. Holloway, R.G. Spencer, N.H. Greig, and J.M. Egan Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats Endocrinology 141 2000 1936 1941
14. I. Kim, T.H. Kim, K. Ma, E.S. Lee, D. Kim, K.T. Oh, D.H. Lee, K.C. Lee, and Y.S. Youn Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy Bioconjug. Chem. 21 2010 1513 1519
15. Y.S. Lee, S. Shin, T. Shigihara, E. Hahm, M.J. Liu, J. Han, J.W. Yoon, and H.S. Jun Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis Diabetes 56 2007 1671 1679
16. H. Kim, H. Park, J. Lee, T.H. Kim, E.S. Lee, K.T. Oh, K.C. Lee, and Y.S. Youn Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes Biomaterials 32 2011 1685 1693
17. Y. Li, X. Zheng, L. Tang, W. Xu, and M. Gong GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1 Peptides 32 2011 1303 1312
18. T.I. Kim, M. Ou, M. Lee, and S.W. Kim Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems Biomaterials 30 2009 658 664
19. P.H. Kim, T.I. Kim, J.W. Yockman, S.W. Kim, and C.O. Yun The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy Biomaterials 31 2010 1865 1874
20. T.I. Kim, M. Lee, and S.W. Kim Efficient GLP-1 gene delivery using two-step transcription amplification plasmid system with a secretion signal peptide and arginine-grafted bioreducible polymer J. Control. Release 157 2012 243 248
21. H. Ah Kim, S. Lee, J.H. Park, S. Lee, B.W. Lee, S.H. Ihm, T.I. Kim, S.W. Kim, K.S. Ko, and M. Lee Enhanced protection of Ins-1 beta cells from apoptosis under hypoxia by delivery of DNA encoding secretion signal peptide-linked exendin-4 J. Drug Target. 17 2009 242 248
22. S. Choi, S. Oh, M. Lee, and S.W. Kim Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes Mol. Ther. 12 2005 885 891
23. E. Wagner, M. Ogris, and W. Zauner Polylysine-based transfection systems utilizing receptor-mediated delivery Adv. Drug Deliv. Rev. 30 1998 97 113
24. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
25. J.M. Egan, A.R. Clocquet, and D. Elahi The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes J. Clin. Endocrinol. Metab. 87 2002 1282 1290
26. D.G. Parkes, R. Pittner, C. Jodka, P. Smith, and A. Young Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro Metabolism 50 2001 583 589
27. D.J. Drucker Enhancing incretin action for the treatment of type 2 diabetes Diabetes Care 26 2003 2929 2940
28. J.A. Davidson, E.B. Parente, and J.L. Gross Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes Arq. Bras. Endocrinol. Metabol. 52 2008 1039 1049
29. P.H. Kim, J. Kim, T.I. Kim, H.Y. Nam, J.W. Yockman, M. Kim, S.W. Kim, and C.O. Yun Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration Biomaterials 32 2011 9328 9342